In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology (SURF), with a price target of $12.00. The company’s shares closed last Monday at $1.47, close to its 52-week low of $1.15.
According to TipRanks.com, Roy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -15.6% and a 27.6% success rate. Roy covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics, Mirati Therapeutics, and Neon Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Surface Oncology with a $12.00 average price target, representing a 654.7% upside. In a report issued on November 13, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.94 and a one-year low of $1.15. Currently, Surface Oncology has an average volume of 57.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
